Brokerages expect Insulet Co. (NASDAQ:PODD) to report $0.04 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Insulet’s earnings, with estimates ranging from ($0.04) to $0.09. Insulet reported earnings per share of ($0.12) during the same quarter last year, which would suggest a positive year over year growth rate of 133.3%. The firm is scheduled to announce its next earnings report on Wednesday, February 20th.
According to Zacks, analysts expect that Insulet will report full year earnings of ($0.09) per share for the current year, with EPS estimates ranging from ($0.23) to ($0.01). For the next year, analysts expect that the firm will post earnings of $0.38 per share, with EPS estimates ranging from $0.14 to $0.61. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Insulet.
Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 1st. The medical instruments supplier reported $0.03 EPS for the quarter, beating the consensus estimate of $0.02 by $0.01. The firm had revenue of $151.10 million for the quarter, compared to analyst estimates of $148.82 million. Insulet had a negative return on equity of 7.95% and a negative net margin of 2.54%. The company’s revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.04) EPS.
PODD has been the topic of several recent research reports. Leerink Swann restated an “outperform” rating and set a $130.00 price target on shares of Insulet in a research report on Tuesday, September 11th. Zacks Investment Research upgraded Insulet from a “hold” rating to a “buy” rating and set a $119.00 price target on the stock in a research report on Monday, October 1st. BidaskClub upgraded Insulet from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 11th. Morgan Stanley raised their price target on Insulet from $96.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 11th. Finally, Oppenheimer set a $100.00 price target on Insulet and gave the stock a “hold” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. Insulet currently has an average rating of “Buy” and an average target price of $99.38.
In other Insulet news, EVP Aiman Abdel-Malek sold 602 shares of the stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $86.60, for a total value of $52,133.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael P. Spears sold 5,043 shares of the stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $86.08, for a total value of $434,101.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,809 shares of company stock valued at $704,659. Company insiders own 3.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Putnam Investments LLC lifted its holdings in Insulet by 2.1% in the 2nd quarter. Putnam Investments LLC now owns 29,224 shares of the medical instruments supplier’s stock worth $2,505,000 after buying an additional 599 shares during the period. Aperio Group LLC lifted its holdings in Insulet by 15.3% in the 2nd quarter. Aperio Group LLC now owns 4,976 shares of the medical instruments supplier’s stock worth $426,000 after buying an additional 660 shares during the period. Swiss National Bank lifted its holdings in Insulet by 1.1% in the 2nd quarter. Swiss National Bank now owns 102,200 shares of the medical instruments supplier’s stock worth $8,759,000 after buying an additional 1,100 shares during the period. Tirschwell & Loewy Inc. lifted its holdings in Insulet by 0.4% in the 2nd quarter. Tirschwell & Loewy Inc. now owns 304,165 shares of the medical instruments supplier’s stock worth $26,067,000 after buying an additional 1,125 shares during the period. Finally, Wasatch Advisors Inc. lifted its holdings in Insulet by 0.4% in the 2nd quarter. Wasatch Advisors Inc. now owns 403,656 shares of the medical instruments supplier’s stock worth $34,593,000 after buying an additional 1,701 shares during the period.
PODD traded down $1.60 on Friday, hitting $88.53. 1,194,329 shares of the company were exchanged, compared to its average volume of 678,250. The company has a debt-to-equity ratio of 3.22, a current ratio of 5.54 and a quick ratio of 5.01. Insulet has a 12 month low of $63.05 and a 12 month high of $108.90. The firm has a market cap of $5.22 billion, a price-to-earnings ratio of -192.46 and a beta of 1.67.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Recommended Story: What factors cause inflation to rise?
Get a free copy of the Zacks research report on Insulet (PODD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.